Synta Pharmaceuticals Corp. is now in Oversold Territory - Tale of the Tape

By
A A A

Synta Pharmaceuticals Corp.'s ( SNTA ) share price has entered into oversold territory with an RSI value of 26.6. The Zacks Consensus Estimate on Synta Pharmaceuticals Corp.'s earnings for the full year period has loss of 0.02 cents over the past two months to $-1.18 per share. Currently, Synta Pharmaceuticals Corp. is a Zacks #2 Rank ("Buy"), suggesting that now might be a good time to get in on ( SNTA ) after its recent drop.

SYNTA PHARMACT (SNTA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Investing Ideas , Stocks

Referenced Stocks: SNTA

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

85,117,424
  • $6.78 ▲ 11.88%
77,261,676
  • $17.53 ▲ 1.56%
61,066,548
  • $6.90 ▲ 2.99%
56,847,440
  • $112.65 ▲ 2.96%
52,788,366
  • $7.78 ▲ 1.83%
50,761,400
  • $25.14 ▲ 2.91%
47,781,237
  • $45.35 ▲ 10.18%
45,664,909
  • $7.17 ▲ 2.14%
As of 12/18/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com